Literature DB >> 19871290

INDUCED RESISTANCE OF THE CENTRAL NERVOUS SYSTEM TO EXPERIMENTAL INFECTION WITH EQUINE ENCEPHALOMYELITIS VIRUS : II. SEROTHERAPY IN WESTERN VIRUS INFECTION.

P K Olitsky1, R W Schlesinger, I M Morgan.   

Abstract

Under none of the experimental conditions here described was treatment of the infection induced by the virus of Western equine encephalomyelitis in mice and guinea pigs with specific hyperimmune rabbit serum effective if begun after the onset of signs of encephalitis. In mice, after intracerebral inoculation of virus, serum was ineffective when given even before that stage. After peripheral introduction of virus in guinea pigs the disease was completely arrested in certain animals by single or multiple doses of antiserum if treatment was begun within 24 to 48 hours after virus inoculation. In others the incubation period was prolonged to 2 or even as long as 7 weeks. In untreated guinea pigs, injection of virus alone led to active immunity in those which survived. Antiserum blocked the antigenicity of active virus in the serum-treated animals. The decrease in titer in the sera of all antiserum-treated animals proceeded at the same rate as in those of control guinea pigs which received antiserum alone. Thus it was not possible to predict which ones would survive and which would succumb after a prolonged incubation period. Delayed fatal disease occurred at a time when the neutralizing antibody of the treated guinea pigs had fallen to a low titer. It is therefore likely that the virus which persisted throughout this long incubation period had been prevented from passing to and infecting other cells but reached them when antibody fell to an ineffective level in the surrounding medium. The relative frequency of such delayed reactions limits to a further extent the degree to which antiserum can be depended on for effective treatment of infection with the virus of equine encephalomyelitis.

Entities:  

Year:  1943        PMID: 19871290      PMCID: PMC2135345          DOI: 10.1084/jem.77.4.359

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  9 in total

1.  Epidemic Influenza.

Authors:  T Francis
Journal:  Bull N Y Acad Med       Date:  1941-04

2.  ENCEPHALOMYELITIS IN MONKEYS.

Authors:  R W Wyckoff
Journal:  Science       Date:  1939-06-09       Impact factor: 47.728

3.  INDUCED RESISTANCE OF THE CENTRAL NERVOUS SYSTEM TO EXPERIMENTAL INFECTION WITH EQUINE ENCEPHALOMYELITIS VIRUS : I. NEUTRALIZING ANTIBODY IN THE CENTRAL NERVOUS SYSTEM IN RELATION TO CEREBRAL RESISTANCE.

Authors:  I M Morgan; R W Schlesinger; P K Olitsky
Journal:  J Exp Med       Date:  1942-10-01       Impact factor: 14.307

4.  INFLUENCE OF AGE ON SUSCEPTIBILITY AND ON IMMUNE RESPONSE OF MICE TO EASTERN EQUINE ENCEPHALOMYELITIS VIRUS.

Authors:  I M Morgan
Journal:  J Exp Med       Date:  1941-07-31       Impact factor: 14.307

5.  ACTIVE IMMUNIZATION OF GUINEA PIGS WITH THE VIRUS OF EQUINE ENCEPHALOMYELITIS : IV. EFFECT OF IMMUNE SERUM ON ANTIGENICITY OF ACTIVE AND INACTIVE VIRUS.

Authors:  H R Cox; P K Olitsky
Journal:  J Exp Med       Date:  1936-07-31       Impact factor: 14.307

6.  INTRAPERITONEAL AND INTRACEREBRAL ROUTES IN SERUM PROTECTION TESTS WITH THE VIRUS OF EQUINE ENCEPHALOMYELITIS : I. A COMPARISON OF THE TWO ROUTES IN PROTECTION TESTS.

Authors:  P K Olitsky; C G Harford
Journal:  J Exp Med       Date:  1938-07-31       Impact factor: 14.307

7.  STUDIES ON EASTERN EQUINE ENCEPHALOMYELITIS : I. HISTOPATHOLOGY OF THE NERVOUS SYSTEM IN THE GUINEA PIG.

Authors:  L S King
Journal:  J Exp Med       Date:  1938-10-31       Impact factor: 14.307

8.  THE FIXATION AND PROTECTION OF VIRUSES BY THE CELLS OF SUSCEPTIBLE ANIMALS.

Authors:  P Rous; P D McMaster; S S Hudack
Journal:  J Exp Med       Date:  1935-04-30       Impact factor: 14.307

9.  EPIDEMIOLOGY OF EQUINE ENCEPHALOMYELITIS IN THE EASTERN UNITED STATES.

Authors:  C Tenbroeck; E W Hurst; E Traub
Journal:  J Exp Med       Date:  1935-10-31       Impact factor: 14.307

  9 in total
  7 in total

1.  The mechanism of active cerebral immunity to equine encephalomyelitis virus; the local antigenic booster effect of the challenge inoculum.

Authors:  R W SCHLESINGER
Journal:  J Exp Med       Date:  1949-05       Impact factor: 14.307

2.  STUDIES ON HERPETIC INFECTION IN MICE : IV. THE EFFECT OF SPECIFIC ANTIBODIES ON THE PROGRESSION OF THE VIRUS WITHIN THE NERVOUS SYSTEM OF YOUNG MICE.

Authors:  C A Evans; H B Slavin; G P Berry
Journal:  J Exp Med       Date:  1946-10-31       Impact factor: 14.307

3.  INFLUENCE OF ANESTHESIA ON EXPERIMENTAL NEUROTROPIC VIRUS INFECTIONS : I. IN VIVO STUDIES WITH THE VIRUSES OF WESTERN AND EASTERN EQUINE ENCEPHALOMYELITIS, ST. LOUIS ENCEPHALITIS, POLIOMYELITIS (LANSING), AND RABIES.

Authors:  S E Sulkin; C Zarafonetis; A Goth
Journal:  J Exp Med       Date:  1946-09-30       Impact factor: 14.307

4.  The persistence of bovine gamma-globulin injected as an antigen into rabbits; a comparison with its previously studied persistence in mice.

Authors:  P D McMASTER; H KRUSE; E STURM; J L EDWARDS
Journal:  J Exp Med       Date:  1954-10-01       Impact factor: 14.307

5.  INDUCED RESISTANCE OF THE CENTRAL NERVOUS SYSTEM TO EXPERIMENTAL INFECTION WITH EQUINE ENCEPHALOMYELITIS VIRUS : III. ABORTIVE INFECTION WITH WESTERN VIRUS AND SUBSEQUENT INTERFERENCE WITH THE ACTION OF HETEROLOGOUS VIRUSES.

Authors:  R W Schlesinger; P K Olitsky; I M Morgan
Journal:  J Exp Med       Date:  1944-09-01       Impact factor: 14.307

6.  Active anaphylaxis to a foreign protein induced in mice by the transfer of tissue from animals previously injected with the protein.

Authors:  P D McMASTER; J L EDWARDS; E STURM
Journal:  J Exp Med       Date:  1955-08-01       Impact factor: 14.307

7.  ENDURING IMMUNITY FOLLOWING VACCINATION OF MICE WITH FORMALIN-INACTIVATED VIRUS OF RUSSIAN SPRING-SUMMER (FAR EASTERN, TICK-BORNE) ENCEPHALITIS : CORRELATION WITH SERUM-NEUTRALIZING AND COMPLEMENT-FIXING ANTIBODIES.

Authors:  J Casals; P K Olitsky
Journal:  J Exp Med       Date:  1945-11-30       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.